Codexis stock jumps on Q4 earnings beat, strong 2026 outlook

The enzyme-engineering platform company exceeded Q4 2025 expectations and provided an upbeat forecast for the year ahead.

Mar. 12, 2026 at 11:39am

Got story updates? Submit your updates here. ›

Codexis (CDXS), a Redwood City, California-based enzyme-engineering platform company, saw its stock rise in premarket trading after reporting better-than-expected Q4 2025 results and providing a strong outlook for 2026.

Why it matters

Codexis' performance is closely watched as an indicator of the health of the broader enzyme-engineering industry, which has seen growing demand from the pharmaceutical, chemical, and renewable energy sectors.

The details

Codexis recorded $38.9 million in revenue for Q4 2025, exceeding analyst expectations. The company attributed the strong results to a deal with pharmaceutical giant Merck (MRK) as well as an overall positive outlook for 2026.

  • Codexis reported its Q4 2025 earnings on March 12, 2026.

The players

Codexis

A Redwood City, California-based enzyme-engineering platform company.

Merck

A major pharmaceutical company that has a deal with Codexis.

Got photos? Submit your photos here. ›

The takeaway

Codexis' strong Q4 2025 performance and optimistic 2026 outlook suggest the enzyme-engineering industry continues to see robust demand, particularly from the pharmaceutical and chemical sectors.